Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California.
Susan Molineaux and Phil Whitcomeref>"Paid Notice: Deaths WHITCOME, DR. PHILIP J."
Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone for treating multiple myeloma, a blood cancer.
[1] At the time of its sale (see below), the company had two earlier-stage programs, an orally-bioavailable proteasome inhibitor for oncology (PR-047), and an agent preferentially targeting the immuno form of the proteasome (PR-957), with potential utility in areas such as rheumatoid arthritis.
At the time of sale, carfilzomib's route of administration was intravenous, and the company was exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers.